Usama Malik
Usama Malik is a highly accomplished professional with a rich background in various industries including healthcare, telecommunications, high-tech, industrials, apparels, and wearable tech.
With extensive experience in leadership roles, Usama has served as the Chief Financial & Chief Business Officer at Immunomedics, where he orchestrated a remarkable restructuring that led to a significant return on investment through a $21B sale to Gilead.
His tenure at Pfizer Inc. saw him as the Vice President and Chief Strategy & Innovation Officer, where he spearheaded transformative initiatives like the $68B Pfizer-Wyeth merger and integration, new R&D and commercial models, and the development of the Biosimilars strategy.
Before his time at Pfizer, Usama excelled at Booz & Company as a leader in healthcare and life science strategy consulting, advising CEOs and executive teams on growth strategies and business transformations.
He also spent years in the telecommunications industry focusing on creating new businesses and investing in disruptive technologies for major telecom providers globally.
Usama's educational background is equally impressive, with graduate coursework in Computer Science and Information Management from The Johns Hopkins University, an MBA in Finance, Strategy, and Entrepreneurship from INSEAD, and a B.Sc in Electrical Engineering with minors in Math & Philosophy from the University of Maryland at College Park.
Throughout his career, Usama has showcased expertise in board and executive leadership, corporate restructuring, public company management, growth acceleration, innovation, and company scaling.
